Home » Stocks » QBIO

Q BioMed Inc. (QBIO)

Stock Price: $1.05 USD -0.04 (-3.67%)
Updated Feb 26, 2021 3:55 PM EST - Market closed
Market Cap 24.58M
Revenue (ttm) 30,000
Net Income (ttm) -13.25M
Shares Out 22.43M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE 98.04
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $1.05
Previous Close $1.09
Change ($) -0.04
Change (%) -3.67%
Day's Open 1.10
Day's Range 1.01 - 1.10
Day's Volume 57,063
52-Week Range 0.9001 - 3


Hide News
  • All
  • Videos
  • Press Releases
PRNewsWire - 1 month ago

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purch...

PRNewsWire - 1 month ago

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug ...

PRNewsWire - 2 months ago

NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a clo...

PRNewsWire - 2 months ago

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is...

About QBIO

Q BioMed, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and U... [Read more...]

Denis D. Corin
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements